linjc16/ctgov huggingface dataset:
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid

Study Overview
=================
Brief Summary
-----------------
Whereas pruritus is a major symptom in bullous pemphigoid, its characteristics and its impact on quality of life have been little studied. The objective of this study is to learn more about pruritus characteristics of patients with bullous pemphigoid, and in consequence to better understand the pathophysiology of pruritus, and then to better treat pruritus in this condition.

Official Title
-----------------
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid

Conditions
-----------------
Bullous Pemphigoid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult pruriginous bullous pemphigoid lately diagnosed. Without PB treatment MMS (Mini Mental State Examination) ≥ 21 In hospitalization or consultation Exclusion Criteria: pregnant woman nursing women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical characteristics of pruritus in patients with bullous pemphigoid | Answers and scores in questionnaire about clinical characteristics of pruritus Demographics characteristics of patients Characteristics of the bullous pemphigoid | Day1 ( when diagnosis of bullous pemphigoid is made) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of pruritus on quality of life in patients with bullous pemphigoid | Score 5D itch scale | Day 1 (when diagnosis of bullous pemphigoid is made ) | 
| Impact of pruritus on quality of life in patients with bullous pemphigoid | score ItchyQol (Itchy Quality of Life) | Day1 (when diagnosis of bullous pemphigoid is made ) | 
| Impact of pruritus on quality of life in patients with bullous pemphigoid | score ABQOL | Day 1 (when diagnosis of bullous pemphigoid is made ) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pruritus, Bullous pemphigoid
Subcapsular Orchiectomy in Men With Klinefelter Syndrome

Study Overview
=================
Brief Summary
-----------------
Men with Klinefelter syndrome undergo unilateral subcapsular ochiectomy, and the removed testicular tissue is examined for presence of sperm and cryopreserved in small pieces for fertility treatment and scientific purposes. Prior to operation blood samples are frozen in a biobank.

Conditions
-----------------
Klinefelter Syndrome

Intervention / Treatment
-----------------
* Procedure: Orchiectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Klinefelter 15-40 years of age Exclusion Criteria: inability to understand the study

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Orchiectomy<br>The patients undergo subcapsular orchiectomy | Procedure: Orchiectomy<br>* The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of testicular sperm |  | Between 1 and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate after ICSI with retrieved testicular sperm |  | participants will be followed for the duration of fertility treatment, an expected average of 6 months |
Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)

Study Overview
=================
Brief Summary
-----------------
Clinical experience investigation (CEI) is to be conducted to confirm the following to characterise safety and efficacy of Tagrisso Tablets in actual clinical use. Incidence of adverse drug reactions (ADRs) in actual clinical use Factors which may affect safety and efficacy of the product (especially analysis of the incidence and risk factors of interstitial lung disease (ILD) events) Information of ADRs not expected from Precautions for Use of the package insert in Japan

Official Title
-----------------
Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)

Conditions
-----------------
All Patients Treated With the Product

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients treated with the product Exclusion Criteria: No Account (NA)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions (ADRs) in actual clinical use | Presence/absence of adverse events (AEs) [any undesirable or unintentional signs (including laboratory abnormalities), symptoms, or diseases whether or not considered causally related to the product] reported during the observation period However, deterioration of a pre-existing lung cancer lesion and lung cancer death should not be reported as an AE. | Up to 12 months |
Detecting Occult Proximal Humeral Neck Fractures Through CT and MRI Tests of Patients With Greater Tuberosity Fractures

Study Overview
=================
Brief Summary
-----------------
Patients with greater tuberosity fractures is becoming increasingly common, as is the number of cases of humeral surgical neck fractures. This study investigated the relationship between size of greater tuberosity fragment and occurrence of humeral surgical neck fractures by using CT or MRI tests.

Detailed Description
-----------------
Some humeral surgical neck fractures can be detected through X-ray of shoulder in patients with greater tuberosity fractures. However, some fractures can not be find through conventional X-ray in such patients unless broader CT or MRI tests are required to confirm diagnoses of humeral surgical neck fractures.

Official Title
-----------------
Third Hospital of Hebei Medical University

Conditions
-----------------
Humeral Greater Tuberosity, Humeral Fractures/ Proximal, Fractures/ Occult

Intervention / Treatment
-----------------
* Diagnostic Test: CT and MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years or older with greater tuberosity fractures and shoulder dislocation/ or not who were acute injured were included Exclusion Criteria: Patients with ipsilateral previous proximal humeral fractures and obviously proximal humeral fractures were excluded。

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with greater tuberosity fractures<br>If humeral surgical neck fractures can be detected through CT or MRI in such groups. | Diagnostic Test: CT and MRI<br>* For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.<br>|
| Dislocation patients with greater tuberosity fractures<br>If humeral surgical neck fractures can be detected through CT or MRI in such groups. | Diagnostic Test: CT and MRI<br>* For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Humeral surgical neck fractures can be detected through CT/MRI. | Some greater tuberosity fractures with/or not shoulder dislocation can combined with humeral surgical neck fractures,which can be detected through CT/MRI | 31/12/2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
occult, proximal humeral neck fractures, greater tuberosity, shoulder dislocation
Early Diagnosis of Asthma in Young Children

Study Overview
=================
Brief Summary
-----------------
The overall aim of the study is an early asthma diagnosis in young children by the use of non-invasive biomarkers of airway inflammation /oxidative stress in exhaled air, and early lung function measurements

Official Title
-----------------
Early Diagnosis of Asthma in Young Children

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: beclomethasondipropionate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 2-3 years, with recurrent respiratory symptoms suggestive of asthma Children aged 2-3 years, with no or minor respiratory symptoms Exclusion Criteria: Mental retardation Cardiac anomalies Congenital malformations Other diseases of the lungs/airways Chronic systemic inflammatory diseases like M. Crohn The inability to perform lung function measurements and/or exhaled air collection

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: beclomethasondipropionate<br>2 x 100 ug dd for two months, via aerochamber | Drug: beclomethasondipropionate<br>* 2 x 100 ug dd for two months, via aerochamber<br>* Other names: Qvar Extra Fijn;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - definite asthma diagnosis - biomarkers in exhaled breath |  | 6 years of age | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, transient wheezing, early diagnosis, exhaled air, nitrogen monoxide, airway resistance
A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.

Official Title
-----------------
A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Conditions
-----------------
Vertigo

Intervention / Treatment
-----------------
* Drug: Merislon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients that have a clinical diagnosis of posterior circulation infarction and vertigo occurring within 1 month after the infarction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Merislon|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in the European Evaluation of Vertigo (EEV) scale in 4 weeks. |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The duration of the vertigo symptom. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vertigo, Posterior circulation infarction
Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate the effectiveness of CoronaVac vaccine, which is more than 90% protective in healthy people, in cancer patients receiving active chemotherapy. In this study, to collect information to measure the amount of antibodies produced by the vaccine in the blood of volunteers with the CoronoVac vaccine and to compare it with healthy volunteers.

Official Title
-----------------
Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.

Conditions
-----------------
Is the Coronovac Vaccine Effective in Patients Receiving Chemotherapy

Intervention / Treatment
-----------------
* Biological: CoronoVAC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group 1 18 years old and above Having completed two doses of CoronoVac vaccine on time Those with a pathological diagnosis of breast cancer or lung cancer Being the first dose of vaccine during active chemotherapy period Ecog performance score 0-1 Patients who signed the informed voluntary consent form Group 2 Over 18 years old Ecog performance score is 0-1 Those who have completed 2 doses of coronovac vaccine within the recommended period Volunteer who signed the informed consent form Exclusion Criteria: For all groups Being confirmed or suspected covid-19 before vaccination Symptomatic covid-19 infection Being addicted to alcohol or drugs Having a fever of 37.8 ° C as a suspect before vaccination Aspleni

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine<br> | Biological: CoronoVAC<br>* SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination<br>|
| Healthy volunteers who received two doses of coronavac vaccine<br> | Biological: CoronoVAC<br>* SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody levels above the defined cut-off | SARS-CoV-2 IgG II ≥ 50.0 AU/ml (positive) and SARSCoV- 2 IgM >1 (positive) | Between the third and sixth weeks after the second dose of vaccine | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronovac, covid-19
A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Study Overview
=================
Brief Summary
-----------------
This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Official Title
-----------------
An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Conditions
-----------------
Hyperparathyroidism, Parathyroid Neoplasms

Intervention / Treatment
-----------------
* Drug: AMG 073


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; * Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; * Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AMG 073|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in serum calcium and PTH |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of cinacalcet |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Severe primary hyperparathyroidism, Parathyroid carcinoma
Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the effectivity of visible light in combination with waterfiltered infrared in treating acne papulopustulosa. The reduction of inflammatory and non-inflammatory lesions within 8 weeks will be measured and compared with the standard treatment with Adapalene.

Official Title
-----------------
Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)

Conditions
-----------------
Acne Papulopustulosa

Intervention / Treatment
-----------------
* Drug: Adapalen
* Radiation: VIS and wIRA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild to moderate acne papulopustulosa according to Burton Scale Stage 3 to 4 At least 5 inflammatory and 5 non-inflammatory lesions in the face Age >= 14 years Exclusion Criteria: pregnant and nursing women Antiandrogen therapy therapy with antibiotics within the last 4 weeks therapy with retinoids within the last 6 months natural or artificial UV-therapy within the last 4 weeks severe acne papulopustulosa according to Burton Scale 5 or 6 Severe systemic condition Secondary acne

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>VIS and wIRA | Radiation: VIS and wIRA<br> <br> |
| Active Comparator: 2<br>VIS, wIRA and Adapalen | Drug: Adapalen<br> <br> Radiation: VIS and wIRA<br> <br> |
| Active Comparator: 3<br>Adapalen | Drug: Adapalen<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction of inflammatory and non-inflammatory lesions within 8 weeks after start of therapy |  |  |
Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are serious diseases with poor prognosis despite recent advances. Currently, pulmonary hypertension (PH) is considered a cell proliferative disorder, which has not been adequately characterized due to the lack of markers. A better understanding of the mechanisms that regulate this proliferative disorder will allow the identification of new therapeutic targets for HP. The objective of the project is to identify cell proliferative processes in severe forms of PH. Patients with PAH (n=20), CTEPH (n=20) and healthy controls (n=20) will undergo characterization of microRNAs (miRNAs) contained within circulating microparticles (MPs) analysis and mitochondrial functionality and FDG-PET to compare cell metabolism in the lungs and the right ventricle between patients and controls.

Official Title
-----------------
Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Drug: fludeoxyglucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with PAH: Hemodynamic diagnosis of precapillary pulmonary hypertension: PAPm ≥25 mmHg, PCWP ≤15 mmHg Exclusion of group 2,3,4 or 5 Patients with CTEPH: Hemodynamic diagnosis of precapillary pulmonary hypertension: PAPm ≥25 mmHg, PCWP ≤15 mmHg Persistence of thrombotic perfusion defects on pulmonary scintigraphy or angioCT, after 3 months or more of correct anticoagulant therapy Healthy subjects No known disease or condition Normal lung function, chest x-ray, EKG and blood chemistry and haematology Exclusion Criteria: Severe comorbidity. Pulmonary, pleural or rib cage disease interfering with FDG-PET acquisition Malignancy with exception of basocellular carcinoma Current smoker or former smoker (last 10 years or more than 10-year-pack). Pregnant or lactating women Hyperglycemia (fasting above 200 mg/dL) Hypersensitivity to the product or its excipients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FDG<br>all patients will undergo a PET scan and will receive 18F fludeoxyglucose | Drug: fludeoxyglucose<br> <br> * Other names: FDG;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FDG uptake in lung parenchyma |  | 1 hour |